2019
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy
Desai VB, Wright JD, Gross CP, Lin H, Boscoe FP, Hutchison LM, Schwartz PE, Xu X. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. American Journal Of Obstetrics And Gynecology 2019, 221: 39.e1-39.e14. PMID: 30853364, PMCID: PMC7006101, DOI: 10.1016/j.ajog.2019.02.051.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAsianBlack or African AmericanComorbidityEndometrial NeoplasmsEndometriosisEthnicityFemaleHispanic or LatinoHumansHysterectomyIncidental FindingsLeiomyomaLeiomyosarcomaMenstruation DisturbancesMetrorrhagiaMiddle AgedObesityPrevalenceRisk AssessmentRisk FactorsSarcomaUnited StatesUterine NeoplasmsUterine ProlapseWhite PeopleYoung AdultConceptsOccult uterine cancerUterine cancerBenign indicationsRisk factorsUterine sarcomaBenign hysterectomyEndometrial carcinomaPredictive valueResearch Cooperative System databaseState cancer registry dataNew York Statewide PlanningHigh negative predictive valueLow positive predictive valueAssociated risk factorsCorpus uteri cancerLarge population-based sampleCancer registry dataPopulation-based sampleAmbulatory surgery centersNegative predictive valuePositive predictive valueRisk prediction modelRace/ethnicityPostmenopausal bleedingPatient characteristics
2017
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy
Wright JD, Desai VB, Chen L, Burke WM, Tergas AI, Hou JY, Accordino M, Ananth CV, Neugut AI, Hershman DL. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. American Journal Of Obstetrics And Gynecology 2017, 217: 59.e1-59.e12. PMID: 28341383, PMCID: PMC5499703, DOI: 10.1016/j.ajog.2017.03.011.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsBreast cancerHormonal therapyPostmenopausal womenGynecologic symptomsCumulative incidenceGynecologic proceduresLimited population-level dataSurveillance testingSelective estrogen receptor modulator tamoxifenEstrogen receptor modulator tamoxifenStudy periodPopulation-based analysisYears of agePopulation-level dataTamoxifen useAsymptomatic womenGynecologic problemsMarketScan databaseGynecologic conditionsPathologic diagnosisGynecologic abnormalitiesGynecologic servicesGynecologic interventionsTamoxifen